Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

May 13

2022

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for the treatment of diabetes, were published online simultaneously by Nature Medicine, an international top medical journal. These two papers described and analyzed the clinical efficacy and safety characteristics of dorzagliatin monotherapy (SEED) in drug-naïve Type 2 diabetes (T2D) patients and the combination therapy of dorzagliatin and metformin (DAWN) in patients who failed in metformin adequacy therapy for the treatment of T2D respectively.

Mar 16

2022

Hua Medicine Announces 2021 Annual Results

Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin.

Feb 21

2022

Hua Medicine Announces Supply Agreement with WuXi STA for Commercial Manufacturing of Dorzagliatin

Hua Medicine (the "Company", Stock Code: 2552.HK) today announces a supply agreement with WuXi STA for the commercial manufacturing of dorzagliatin, a first-in-class oral therapy for type 2 diabetes (T2D). This commercial supply agreement between Hua Medicine and WuXi STA will further enhance their current collaboration.

Sep 26

2021

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Hua Medicine (the "Company", or "Hua Medicine", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference (the "CBIIC"), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers, presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission.

Sep 23

2021

Hua Medicine's SEED Researchers to Present Key Research Results on Diabetes Remission at the China BioMed Innovation and Investment Conference

Hua Medicine (the "Company", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference to be held on September 25-27, 2021 in Suzhou, China (the "CBIIC"), select researchers participating in the Hua Medicine Phase III SEED Study ("SEED Study", also known as HMM0301)

Sep 15

2021

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). Under the agreement both companies will cooperate more closely in logistics warehousing, supply chain management and channel data analysis, and will jointly promote the commercialization of Hua Medicine's global first-in-class glucokinase activator (GKA), dorzagliatin, for its market launch in China.

Aug 19

2021

Hua Medicine Announces 2021 Interim Results

Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").

Jun 21

2021

Hua Medicine to present additional dorzagliatin trials data at ADA 2021

Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the Company will be giving 3 important presentations, presenting additional clinical data from several trials of its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 81st American Diabetes Association (ADA) Annual Scientific Sessions.

May 31

2021

Hua Medicine to present additional dorzagliatin data at ADA 2021

Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the Company will present additional clinical research analysis data of its world's first new drug, glucokinase activator (GKA) dorzagliatin, at the 81st American Diabetes Association (ADA) Annual Scientific Sessions. The ADA Annual Scientific Sessions will be held online from June 25 to 29, 2021.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.

人生就是搏尊龙(中国优质)股份有限公司人生就是搏尊龙

Media

Company News

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Hua Medicine Announces 2021 Annual Results

Hua Medicine Announces Supply Agreement with WuXi STA for Commercial Manufacturing of Dorzagliatin

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Hua Medicine's SEED Researchers to Present Key Research Results on Diabetes Remission at the China BioMed Innovation and Investment Conference

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Hua Medicine Announces 2021 Interim Results

Hua Medicine to present additional dorzagliatin trials data at ADA 2021

Hua Medicine to present additional dorzagliatin data at ADA 2021